Your browser doesn't support javascript.
loading
Sertoli-Leydig cell tumor associated with a germline DICER1 pathogenic variant diagnosed during pregnancy: Considerations for treatment, surveillance, and prevention.
Wang, Joyce Y; Ma, Kimberly K; Reiter, Daniel J; Torvie, Ana; Swisher, Elizabeth M.
Afiliación
  • Wang JY; Department of Obstetrics & Gynecology, University of Washington, Seattle, WA, United States.
  • Ma KK; Department of Obstetrics & Gynecology, University of Washington, Seattle, WA, United States.
  • Reiter DJ; Department of Pathology, University of Washington, Seattle, WA, United States.
  • Torvie A; Northwest Women's HealthCare, Seattle, WA, United States.
  • Swisher EM; Department of Obstetrics & Gynecology, University of Washington, Seattle, WA, United States.
Gynecol Oncol Rep ; 48: 101215, 2023 Aug.
Article en En | MEDLINE | ID: mdl-37334322
ABSTRACT
•This is the first report of a germline DICER1-associated Sertoli-Leydig cell tumor (SLCT) diagnosed in pregnancy.•SLCT is linked to DICER1 pathogenic variants, but little is known about management of DICER1-associated SLCT.•There is an extended risk for metachronous SLCT in patients with germline DICER1 pathogenic variants who retain an ovary.•Prophylactic contralateral salpingo-oophorectomy may be offered with shared decision making to patients with inherited SLCT.•Genetic testing for DICER1 should be offered to all patients with moderately or poorly differentiated SLCT.
Palabras clave

Texto completo: 1 Bases de datos: MEDLINE Tipo de estudio: Diagnostic_studies / Prognostic_studies / Risk_factors_studies / Screening_studies Idioma: En Revista: Gynecol Oncol Rep Año: 2023 Tipo del documento: Article País de afiliación: Estados Unidos

Texto completo: 1 Bases de datos: MEDLINE Tipo de estudio: Diagnostic_studies / Prognostic_studies / Risk_factors_studies / Screening_studies Idioma: En Revista: Gynecol Oncol Rep Año: 2023 Tipo del documento: Article País de afiliación: Estados Unidos